» Articles » PMID: 23331854

Macrovascular Complication Phenotypes in Type 2 Diabetic Patients

Overview
Publisher Biomed Central
Date 2013 Jan 22
PMID 23331854
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Macrovascular diseases (MVD) in type 2 diabetes mellitus (T2DM) are often considered all together, without discriminating the areas involved. The aim of our study was to analyse MVD prevalence in a large population of T2DM patients by dividing the cases into subgroups according to MVD sites (NMVD, no MVD; NSCS, non-significant carotid stenosis; CBVD, cerebrovascular disease; CAD, coronary artery disease; PAD, peripheral artery disease; PVD, polyvascular disease) and studying the anthropometric, clinical and laboratory parameters in each group.

Methods: A diabetic outpatient cohort (n = 1199) was retrospectively studied. Demographic, clinical and laboratory parameters were included in analyses. A thorough cardiovascular history as documented by previous medical records (including medical and hospital records) and vascular laboratory studies (including standardised electrocardiogram, echocardiogram, provocative tests for cardiac ischaemia, ankle/brachial index, duplex ultrasonography of the carotid and lower limbs and, in selected cases, computed tomography angiography, carotid and peripheral arteriography and evaluation of transcutaneous oxygen pressure), was collected for all of the patients. Standardised procedures were used to assess microvascular complications as well as metabolic syndrome (Mets).

Results: The unadjusted MVD prevalence was 46.4% among the participants. The majority of patients with MVD were in the PVD group. In the multivariate analysis, age, male sex and diabetes duration were independent risk factors for PAD and PVD (P < 0.01). A low HDL-C value was an independent risk factor in the CAD and PVD groups (P = 0.03). Very high frequencies of MetS were observed in the PAD and PVD groups (94.9 and 95.7% respectively). The most MetS diagnostic criteria were recorded among members of the CAD group (all or all-1 criteria were present in 73% of patients). The average age in the CAD group (64.5 y) was comparable to that of the NMVD group. Microvascular complications were more frequent in the PAD and PVD patients.

Conclusion: Phenotypic heterogeneity is associated with different macrovascular complications in T2DM patients. These findings might have clinical implications for developing diagnostic and therapeutic strategies targeting type 2 diabetes.

Citing Articles

Association between high sensitivity cardiac troponin and mortality risk in the non-diabetic population: findings from the National Health and Nutrition Examination Survey.

Liu L, Cheng Y, Xu A, Cheung B Cardiovasc Diabetol. 2023; 22(1):296.

PMID: 37904214 PMC: 10617237. DOI: 10.1186/s12933-023-02003-2.


Luseogliflozin and caloric intake restriction increase superoxide dismutase 2 expression, promote antioxidative effects, and attenuate aortic endothelial dysfunction in diet-induced obese mice.

Kawade S, Ogiso K, Shayo S, Obo T, Arimura A, Hashiguchi H J Diabetes Investig. 2023; 14(4):548-559.

PMID: 36729938 PMC: 10034951. DOI: 10.1111/jdi.13981.


Influence of hepatitis B virus on the prevalence of diabetes complications in patients with type 2 diabetes.

Liu X, Zhou Y J Diabetes Investig. 2022; 14(3):429-434.

PMID: 36510700 PMC: 9951573. DOI: 10.1111/jdi.13954.


Potential therapeutic role of pyroptosis mediated by the NLRP3 inflammasome in type 2 diabetes and its complications.

Li X, Xiao G, Guo T, Song Y, Li Q Front Endocrinol (Lausanne). 2022; 13:986565.

PMID: 36387904 PMC: 9646639. DOI: 10.3389/fendo.2022.986565.


Targeting NLRP3 Inflammasome in the Treatment Of Diabetes and Diabetic Complications: Role of Natural Compounds from Herbal Medicine.

Bai Y, Mu Q, Bao X, Zuo J, Fang X, Hua J Aging Dis. 2021; 12(7):1587-1604.

PMID: 34631209 PMC: 8460305. DOI: 10.14336/AD.2021.0318.


References
1.
. Economic costs of diabetes in the U.S. In 2007. Diabetes Care. 2008; 31(3):596-615. DOI: 10.2337/dc08-9017. View

2.
Gurfinkel R, Joy T . Anacetrapib: hope for CETP inhibitors?. Cardiovasc Ther. 2010; 29(5):327-39. DOI: 10.1111/j.1755-5922.2010.00142.x. View

3.
. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

4.
Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L . HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care. 2002; 25(7):1135-41. DOI: 10.2337/diacare.25.7.1135. View

5.
Milicevic Z, Raz I, Beattie S, Campaigne B, Sarwat S, Gromniak E . Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care. 2008; 31 Suppl 2:S155-60. DOI: 10.2337/dc08-s240. View